Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Artiva Biotherapeutics Q3 2026 Results: Net Loss of $28.8M, Loss Widens

Artiva Biotherapeutics is undergoing a significant strategic shift, including the wind-down of its AlloNK development program and a workforce reduction to preserve capital. The company is currently evaluating strategic alternatives to maximize stockholder value while managing its remaining clinical close-out and intellectual property activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-28.8-21.5
EPS (diluted, $ a share)$-0.56$-0.88

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ARTV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Artiva Biotherapeutics, Inc.: key numbers

Share price
$3.86Close, Nov 17
Market cap
$191M
Shares outstanding
49.43MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Artiva Biotherapeutics, Inc.

All →
4:03 PM ET 8-K
Leadership Change

Artiva Biotherapeutics Leadership Change

Elizabeth Hougen resigned from the Board of Directors of Artiva Biotherapeutics as a Class III Director, effective November 11, 2026. The company stated her departure was not due to any disagreement regarding operations, policies, or practices.

4:08 PM ET 8-K/A
Business Update

Artiva Biotherapeutics Business Update

Artiva Biotherapeutics is implementing a wind-down of its operations, including the discontinuation of its AlloNK cell therapy candidate and a 94% reduction in workforce. The company estimates it will incur $27 million to $35 million in total charges, including up to $15 million for clinical trial close-out and up to $20 million for severance and termination costs. The workforce reduction is expected to be completed in the first quarter of 2027 as the company explores strategic alternatives.

4:06 PM ET Form 4
Insider Selling

Artiva Biotherapeutics Chief Tech Operations Officer Christopher Horan Sells $43.6K of Stock

Christopher Horan, Chief Tech Operations Officer, sold 10,423 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $43.6K in total on Nov 2, 2026. Shares held after the trade: 302,321 (-3.3%).

Value
$43.6K
Shares
10,423
Price
$4.18
Role
Chief Tech Operations Officer
Holding change
-3.3%
Trade date
Nov 2, 2026
4:06 PM ET Form 4
Insider Selling

Artiva Biotherapeutics COO, CLO, Compliance Officer Jennifer Bush Sells $35.3K of Stock

Jennifer Bush, COO, CLO, Compliance Officer, sold 8,439 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $35.3K in total on Nov 2, 2026. Shares held after the trade: 357,720 (-2.3%).

Value
$35.3K
Shares
8,439
Price
$4.18
Role
COO, CLO, Compliance Officer
Holding change
-2.3%
Trade date
Nov 2, 2026
4:05 PM ET Form 4
Insider Selling

Artiva Biotherapeutics CEO Fred Aslan Sells $260K of Stock

Fred Aslan, CEO, sold 62,178 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $260K in total on Nov 2, 2026. Shares held after the trade: 1,457,428 (-4.1%).

Value
$260K
Shares
62,178
Price
$4.18
Role
CEO
Holding change
-4.1%
Trade date
Nov 2, 2026
8:30 AM ET 8-K
Business Update

Artiva Biotherapeutics Business Update

Artiva Biotherapeutics is halting all development of its lead cell therapy candidate AlloNK (AB-101) and implementing a 94% workforce reduction after clinical data failed to meet durability thresholds and two patient deaths occurred. The company has engaged Leerink Partners to explore strategic alternatives, including a potential merger, sale, or liquidation, while reporting a preliminary cash balance of $319.1 million.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.